News & Updates

Treatment with dupilumab substantially improves symptoms, quality of life, and other outcomes in patients with atopic hand and foot dermatitis (H/F AD), with an acceptable safety profile, results of a study have shown.

Air pollutants appear to contribute to the increased incidence of atopic dermatitis (AD), results of a Taiwan study have shown.

Ambient particulate matter concentrations and rainfall are independently associated with the number of outpatient visits for atopic dermatitis in Singapore, according to a study.

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.

Atopic dermatitis (AD) does not seem to induce an increase in the risk of venous thromboembolism (VTE) when considering underlying risk factors, suggests a study. Moreover, patients with AD show a lower VTE risk than those with rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), or ankylosing spondylitis (AS).